Pulmonary surfactant is a potential endogenous inhibitor of proteolytic activation of Sendai virus and influenza A virus  by Kido, Hiroshi et al.
Volume 322, number 2, 115-119 FEBS 12381 
0 1993 Federation of European Biochemical Societies 00145793/93/%6.00 
May 1993 
Pulmonary surfactant is a potential endogenous inhibitor of proteolytic 
activation of Sendai virus and influenza A virus 
Hiroshi Kido”, Kentaro Sakaib, Yasuo Kishinob and Masato Tashiro” 
“Division of Enzyme Chemistry, Institute for Enzyme Research, ‘Department of Nutrition, School of Medicine, The University of 
Tokushima, Tokushima 770, Japan and ‘Department of Virology, Jichi Medical School, Tochigi 329-04, Japan 
Received 8March 1993 
The pathogenicities of influenza viruses and paramyxoviruses have been proposed to be primarily determined by a host cell protease that activates 
viral infectivity by proteolytic leavage of the envelope glycoproteins. We recently isolated a trypsin-type ndoprotease, named tryptase Clara, from 
rat bronchial and bronchiolar epithelial Clara cells, which is secreted into the airway lumen and activates Sendai virus and influenza A virus 
proteolytically. We report here that surfactant in the bronchial fluid inhibited tryptase Clara specifically, having a K, value of 0.13 PM, and inhibited 
the proteolytic activations by tryptase Clara in vitro and in organ cultures of rat lung. Intranasal infection of rats with Sendai virus was shown 
to stimulate secretion of tryptase Clara without changing the amount of surfactant in the bronchial lumen, resulting in a preferable condition for 
proteolytic viral activation and multiplication. 
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1. INTRODUCTION that activates the envelope glycoprotein precursors 
I5,111. 
Influenza and parainfluenza viruses are important 
causative agents of respiratory infections. Control of 
infections has been a major subject of virus research. 
Post-translational proteolytic cleavage of envelope 
glycoprotein precursors, such as FO of Sendai virus 
(murine parainfluenza virus type 1) and HA of influenza 
viruses, is essential for the expression of infectivity of 
these viruses and multiple cycles of viral replication 
[l-5]. The HA’s of mammalian influenza viruses and F, 
of Sendai virus have a single arginine residue in a con- 
sensus cleavage motif, Gln (or Glu)-X-Arg, [3,6-81. 
These envelope glycoprotein precursors have been re- 
ported to be cleaved in vitro by several proteases, such 
as trypsin in culture systems [2,9] and the clotting factor 
Xa in the allantoic fluid of chick embryos [lo], and they 
are not activated by the ubiquitous host protease 
present in various cell types [3,9,11]. Sendai virus and 
mammalian influenza viruses, however, are specifically 
pneumotropic in vivo, infecting only bronchial and 
bronchiolar epithelial cells, suggesting the presence of 
a specific trypsin-like protease in the respiratory tract 
Recently, we isolated a novel trypsin-like protease, 
named tryptase Clara, from rat lung [13]. This protease 
is present only in non-ciliated secretory cells (Clara 
cells) of the bronchial and bronchiolar epithelia of rats, 
and is secreted into the airway lumen. Purified tryptase 
Clara converts F,, of Sendai virus to its subunits, F, and 
F, [14], and HA of influenza A/Aichi/2/68(H3N2) to 
HA, and HA, [13] and activates the infectivity of these 
viruses in a dose-dependent manner in vitro. Antibody 
against tryptase Clara inhibits Sendai virus activation 
in the lungs of infected rats and suppresses multiple 
cycles of viral replication and pathological changes in 
rat lung [14]. Thus tryptase Clara is considered to be a 
primary host factor involved in the pneumopathogen- 
icity of these viruses. 
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The physiological role of tryptase Clara is unknown, 
but the activity of this enzyme, like those of many pro- 
teases, may be strictly regulated by an endogenous in- 
hibitor(s). To identify this endogenous inhibitor(s), we 
searched for an inhibitor of tryptase Clara in airway 
lavage fluid of rats. Results showed that surfactant, 
which is secreted mainly by alveolar type II cells, and 
to a lesser extent by bronchiolar epithelial Clara cells 
[I 51, is a specific endogenous inhibitor of tryptase Clara. 
In this paper, we describe the inhibitory effects of pul- 
monary surfactant on proteolytic activation of Sendai 
virus and influenza virus in vitro and in organ cultures 
of infected rat lung. We also discuss the potential role 
of pulmonary surfactant in pneumopathogenic viral in- 
fections. 
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2. MATERIALS AND METHODS 
2. I. Materials 
Tryptase Clara from rat lung, and pulmonary surfactant and surfac- 
tant protein A from rat alveolar lavage fluid, were purified by the 
methods of Kido et al. [l3], and Sakai et al. [16], respectively. L-a- 
Phosphatidylcholine, L-a-phosphatidyl+serine and L-a-phosphati- 
dyl-m-glycerol were from Sigma. All other reagents were commercial 
products of the highest grade available. 
2.2. Enzyme and inhibitor assays 
Amidolytic activation of tryptase Clara was assayed using the syn- 
thetic peptide, Boc-Gln-Ala-Arg-MCA, as substrate, as described [13]. 
Trypsin and mast cell tryptase were measured with Boc-Phe-Ser-Arg- 
MCA as substrate, plasmin with Boc-Val-Leu-Lys-MCA, and factor 
Xa with Boc-Ile-Glu-Gly-Arg-MCA. For assay of the effects of sur- 
factant and related compounds on the activity of each protease, the 
enzyme was preincubated with surfactant or surfactant protein A in 
water or phospholipids in ethanol for 5 min at 25°C and then residual 
activity was measured by addition of the substrate. The concentration 
of ethanol in the reaction mixture did not exceed 1%. The inhibition 
constant (K,) for surfactant was determined from a Dixon plot. 
2.3. Radioisotope labeling of virus and gel electrophoresis 
Sendai virus was labeled with [-‘H]glucosamine in LLC-MK2 cells 
and purified as described previously [I I]. Purified inactive Sendai virus 
suspended in PBS deficient in Ca2’ and Mg’+, pH 7.2, was treated with 
proteases in 100 mM Tris-HCI buffer, pH 7.2, for 10 min at 37°C. 
Reactions were terminated by adding 100 ,ug/ml of aprotinin and the 
viral polypeptides were separated by SDS-PAGE under reducing con- 
ditions followed by fluorography [13]. 
2.4. Preparation of bronchoalveolarjuid and Western immunoblotting 
Bronchoalveolar lavage was collected as described previously [13]. 
The lavage fluid was centrifuged at 600 x g for 15 min at 4’C to 
remove cells and concentrated to 0.5 ml by Diaflow ultrafiltration with 
a YM-30 membrane. The concentrated samples were separated by 
SDS-PAGE (l&20% gradient), transferred electrophoretically to an 
Immobilon transfer membrane and immunoblotted with 1 :l,OOO dilu- 
tion of an affinity purified anti-tryptase Clara antibody (1.24 mg/ml), 
or 1:200 dilution of anti-rat pulmonary surfactant protein A (0.5 
mg/ml). Bound antibodies were detected by the anti-rabbit alkaline 
phosphatase method [13]. The resulting bands were scanned with a 
densitometer (Shimazu CS-9000). 
2.5. In vitro activations of Sendai virus and influenza A virus infectivi- 
ties 
Non-activated (non-infectious) Sendai virus and influenza A virus 
were prepared in LLC-MK2 cells and MDCK cells, respectively, as 
described by Tashiro et al. [14,17J. Virus suspensions in PBS, pH 7.2, 
were treated with various concentrations of tryptase Clara or trypsin 
for 10-20 min at 37”C, and reactions were stopped by adding 100 fig 
per ml of aprotinin. Activation of infectivity was assayed by the im- 
munofluorescent cell-counting method [5]. 
2.6. Organ block cultures of rat lung 
The lung block culture method described for mice [18] was applied 
to rats with minor modifications. SPF, 3-week-old male CD(SD) rats 
were infected intranasally with lo4 plaque forming units of active 
Sendai virus. After 2 h, the rats were sacrificed and their lungs were 
removed and cut into blocks. Organ blocks were then incubated in 
MEM at 34”C, and at the indicated times they were homogenized and 
assayed for infectivity as described previously [5]. 
3. RESULTS 
3.1. Effects of pulmonary surfactant and related com- 
pounds on the activity of tryptase Clara 
In a search for an inhibitor(s) of tryptase Clara in the 
bronchial lavage fluid of rats, we found that pulmonary 
surfactant is a potent inhibitor of the protease. The 
inhibition was non-competitive and the Ki value of the 
purified surfactant was 0.13 PM. However, phosphati- 
dylcholine, a major component of surfactant, and minor 
components, such as surfactant protein A, phosphati- 
dylglycerol and phosphatidylserine [ 191, by themselves 
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Fig. 1. Inhibitory effects of surfactant on activations of Sendai virus (A), and influenza AIAichi/2/68(H3N2) (B) by proteases in vitro. Tryptase 
Clara (5Opg/ml, 0) and trypsin (10 &ml, A) were preincubated with surfactant at the indicated concentrations at 0°C for 20 min. Then the mixtures 
were incubated with inactive Sendai virus grown in LLC-MK2 cells (A, 0) or inactive influenza A virus grown in MDC K cells (B, 0) for 20 min 
with tryptase Clara, or for 10 min with trypsin at 3’7°C as described in section 2. The infectivities of the viruses were assayed by the immunofluo- 
rescent cell-counting method [5] using LLC-MK2 cells for Sendai virus (A) and MDCK cells for influenza A virus (B). The infectivity of active 
virus grown in embryonated chicken eggs (0) after treatment with surfactant was also measured. Concentrations of surfactant are expressed as 
those of phospholipids in the samples. CIU, cell infecting unit [5]. 
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Tryptase Clara caused an up to lOO-fold increase in the 
infectivity of both inactive viruses. Surfactant inhibited 
the viral activation by tryptase Clara concentration de- 
pendently, but did not inhibit the activation by trypsin 
(Fig. 1). In addition, surfactant itself did not affect the 
infectivities of active viruses grown in the allantoic cav- 
ity of chick embryos. 
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Fig. 2. Effect of surfactant on proteolytic cleavage of F0 of Sendai 
virus by tryptase Clara. Trypsin (10 &/ml, lanes l-3) and tryptase 
Clara (50 fig/ml, lanes 4-9) were preincubated without surfactant 
(lanes 1 and 4) or with 0.26 mg/ml (lanes 2 and 5), 0.52 mg/ml (lane 
6) 0.78 mg/ml (lane 7), 1 mg/ml (lanes 3 and 8) 3.0 mg/ml (lane 9) of 
surfactant in 20 ,LL~ of 100 mM Tris-HCI buffer, pH 7.2, at 0°C for 5 
min. Then [‘Hlglucosamine-labeled inactive Sendai virus (lane 10) was 
treated with the reaction mixtures at 37°C for 10 min as described in 
section 2. The viral polypeptides were separated by SDS-PAGE under 
reducing conditions followed by fluorography. Concentrations of sur- 
factant are expressed as those of phospholipids in the samples. HN, 
haemagglutinin euraminidase. 
had no effect. Surfactant reconstituted with phosphati- 
dylcholine, phosphatidylglycerol, surfactant protein A 
and phosphatidylserine in a ratio of 67.3:19.3:10.2:3.2 
by weight, showed comparable inhibitory activity, with 
a Ki value of 0.64 PM. These results suggest that the 
inhibition by surfactant is due to a complex of the 
phospholipids and surfactant protein A. It should also 
be noted that the inhibition was specific for tryptase 
Clara. The other trypsin-type proteases, such as trypsin, 
factor Xa, plasmin and rat mast cell tryptase [20], were 
not inhibited at all by surfactant (data not shown). 
3.2. Inhibitory effects of surfactant on activations ofSen- 
dai and influenza viruses in vitro 
To determine whether surfactant inhibits the prote- 
olytic activations of Sendai and influenza viruses by 
tryptase Clara, we examined the infectivities of inactive 
Sendai and influenza AiAichil2168 (H3N2) viruses after 
in vitro activation by tryptase Clara or trypsin that had 
been preincubated with various concentrations of sur- 
factant for 20 min at 0°C. Infectivity was measured by 
the immunofluorescent cell-counting method [5], in 
which only the number of activated viruses are counted. 
We next examined whether surfactant inhibits prote- 
olytic cleavage of the F, protein of Sendai virus by 
tryptase Clara. For this, the enzyme was preincubated 
with various concentrations of surfactant for 5 min at 
0°C and then tested for proteolytic cleavage of [3H]glu- 
cosamine-labeled inactive Sendai virus grown in LLC- 
MK2 cells. The results of SDS-PAGE analysis are 
shown in Fig. 2, together with those for trypsin. Surfac- 
tant inhibited the cleavage of F, to its subunits. F, and 
F,, by tryptase Clara dose dependently, but not at all 
the cleavage by trypsin. Proteolytic cleavage of HA of 
influenza A/Aichi virus by tryptase Clara was also in- 
hibited by pulmonary surfactant (data not shown). 
3.3. Inhibition of Sendai virus activation by surfactant in 
organ cultures of rat lung 
We examined the effect of surfactant on Sendai virus 
activation using block cultures of infected rat lung. The 
results in Fig. 3 also show inhibition of Sendai virus 
activation by surfactant. In culture medium with surfac- 
tant (50 pg/ml), about 90% of the progeny virus re- 
mained unactivated, and so viral replication was sup- 
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Fig. 3. Inhibitory effect of surfactant on Sendai virus activation in 
organ cultures of rat lung. SPF, 3-week-old male CD (SD) rats were 
infected intranasally with lo4 plaque forming units of active Sendai 
virus. After 2 h, lung block cultures were prepared as described in 
section 2 and incubated at 34°C with MEM in the absence (-) 
orpresence (----) of 50 pug/ml of surfactant. At the indicated 
times, organ blocks and media were collected and tissue homogenates 
were assayed for total virus (0) and activated virus (0) yield as 
described previously (51. 
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Fig. 4. Alterations in the activity and amount of tryptase Clara and 
surfactant in bronchial lavage fluid after intranasal infection with 
Sendai virus. Three-week-old, male SPF rats of the CD (SD) strain 
were treated intranasally with 2 x lo4 plaque forming units of active 
Sendai virus (-) or saline (----). Then their lungs were lavaged once 
at the indicated times with 3 ml of sterile saline to obtain 2.5 ml of 
lavage fluid. Cell-free lavage fluid was concentrated to 0.5 ml and an 
aliquot (20 ~1) of the sample was separated by SDS-PAGE (l&20% 
gradient), transferred electrophoretically to an Immobilon PVDF 
membrane and developed with anti-tryptase Clara (0,O) or anti- 
surfactant protein A antibody (W,[7) as described in section 2. The 
resulting bands were quantified by scanning with a densitometer. The 
proteolytic activity of tryptase Clara in lavage fluid (&I) was calcu- 
lated from measurements of the activity that was able to be absorbed 
by anti-tryptase Clara IgG-coupled Sepharose 4B, with Boc-Gln-Ala- 
Arg-MCA as substrate. Data are means f S.E.M. (n = 3). 
pressed to about 10% of the control value. The inhib- 
itory effects on viral activation and replication were not 
observed after absorption of surfactant by anti-surfac- 
tant protein A antibody (data not shown). These effects 
of surfactant were quite similar to those of antibody 
against tryptase Clara on Sendai virus activation [14], 
supporting our previous postulates that tryptase Clara 
is a major activating protease of Sendai virus in rat lung, 
and that viral activation occurs extracellularly in the 
airway lumen [ 141. 
3.4. Sendai virus infection stimulates ecretion of tryp- 
tase Clara but not of surfactant in the airway lumen 
When rats were infected intranasally with Sendai 
virus, tryptase Clara with a molecular mass of 28.5 kDa, 
a secretory form in the bronchial lavage fluid [ 131, was 
increased significantly in both amount and activity after 
inoculation for 12-24 h, whereas the amount of surfac- 
tant remained almost constant, as shown in Fig. 4. 
These findings indicate that infection of rats with Sendai 
virus stimulates ecretion of tryptase Clara, but not of 
surfactant, resulting in enhancement of proteolytic acti- 
vation of viral infectivity and, in preferable conditions, 
for viral multiplication in vivo. 
4. DISCUSSION 
The present study showed that pulmonary surfactant 
purified from bronchoalveolar lavage fluid of rat inhib- 
its the proteolytic activations of Sendai virus and influ- 
enza A virus by tryptase Clara in vitro, and that it also 
inhibits Sendai virus activation in organ cultures of rat 
lung. To our knowledge, this is the first report of the 
inhibitory effect of pulmonary surfactant on proteolytic 
activation of envelope glycoprotein precursors of vi- 
ruses. Pulmonary surfactant, a lipoprotein complex, has 
been reported to coat alveolar epithelium and to lower 
the surface tension at the air-liquid interface. Recent 
studies also indicated that pulmonary surfactant and its 
apoprotein are important in the host defense system in 
the lung, increasing phagocytosis by mononuclear pha- 
gocytes [21] and uptake of liposomes by alveolar mac- 
rophages [22]. In addition to these functions, we found 
that pulmonary surfactant specifically inhibited the pro- 
teolytic activity of tryptase Clara in a non-competitive 
fashion with a relatively low Ki value of 0.13 ,uM, sug- 
gesting that it is a potential endogenous inhibitor of 
tryptase Clara. Surfactant from bovine lung causes sim- 
ilar inhibition of the activity of tryptase Clara and pro- 
teolytic activation of the viruses by tryptase Clara (data 
not shown). Neither phospholipids nor surfactant pro- 
tein A inhibited the enzyme activity, but the inhibitory 
activity was restored by reconstitution of surfactant 
with these compounds. There is no sequence homology 
between surfactant protein A and Kunitz-type protease 
inhibitors of tryptase Clara, such as aprotinin and soy- 
bean trypsin inhibitor [13]. Inhibition of enzyme activi- 
ties by phospholipids and fatty acids have been re- 
ported: chymase and ol-chymotrypsin are inhibited by 
fatty acids [23], granulocyte elastase by cis-unsaturated 
fatty acids [24], phospholipase A by phosphati- 
dylcholine [25], and glutamate dehydrogenase by 
phosphatidylserine [26]. Thus, we speculate that hydro- 
phobic interaction of tryptase Clara with pulmonary 
surfactant, a complex of phospholipids and surfactant 
protein A, might alter the conformation of the enzyme, 
resulting in inhibition of its enzyme activity. 
We have recentry shown that that ploteotytic activa- 
tion of Sendai virus occurs mainly extracellular in the 
lumen of the respiratory tract [14]. In intact animals, the 
activity of tryptase Clara may be suppressed at a low 
level by a physiological concentration of endogenous 
inhibitor, such as surfactant, in the bronchial lumen, 
since when inactive Sendai virus is inoculated intrana- 
sally into mice, little uncleaved F, is converted to an 
active form in the lung [5]. Although the significance of 
the effect of surfactant on tryptase Clara in vivo cur- 
rently remains unclear, after infection by activated Sen- 
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dai virus the proteolytic activity in the lumen was en- 
hanced by increased secretion of the enzyme from Clara 
cells without changing the amount of surfactant, result- 
ing in preferable conditions for proteolytic activation 
and multiplication of progeny virus. An induced imbal- 
ance between the amount of tryptase Clara and that of 
surfactant by activated virus may be responsible for 
pneumopathogenesis of Sendai virus infection. 
Van Daal et al. [27,28] recently reported that intratra- 
cheal administration of surfactant is a promising 
method of therapy in experimental models of adult res- 
piratory distress syndrome associated with Sendai virus 
pneumonia in rats and influenza A pneumonia in mice. 
They showed that supplementation of surfactant signif- 
icantly improved gas exchange by increasing compli- 
ance and the lung volume, and also reduced alveolar 
and bronchiolar edema caused by inflammation. In ad- 
dition to these effects of surfactant on gas exchange and 
edema, its effect as an inhibitor of proteolytic activation 
of viruses described here indicates that it should be 
therapeutically effective in viral pneumonia. 
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